US 12,168,023 B2
Inhibitors of adenosine 5′-nucleotidase
Laurent Pierre Paul Debien, San Francisco, CA (US); Jaroslaw Kalisiak, Newark, CA (US); Kenneth V. Lawson, San Francisco, CA (US); Manmohan Reddy Leleti, Dublin, CA (US); Erick Allen Lindsey, San Diego, CA (US); Dillon Harding Miles, Berkeley, CA (US); Eric Newcomb, Boulder, CO (US); Jay Patrick Powers, Sisters, OR (US); Brandon Reid Rosen, San Mateo, CA (US); and Ehesan Ul Sharif, Castro Valley, CA (US)
Assigned to Arcus Biosciences, Inc., Hayward, CA (US)
Filed by Arcus Biosciences, Inc., Hayward, CA (US)
Filed on Apr. 8, 2024, as Appl. No. 18/629,820.
Application 18/629,820 is a continuation of application No. 18/610,851, filed on Mar. 20, 2024.
Application 18/610,851 is a continuation of application No. 18/364,141, filed on Aug. 2, 2023, abandoned.
Application 18/364,141 is a continuation of application No. 18/065,577, filed on Dec. 13, 2022, abandoned.
Application 18/065,577 is a continuation of application No. 17/741,296, filed on May 10, 2022, abandoned.
Application 17/741,296 is a continuation of application No. 17/514,131, filed on Oct. 29, 2021, abandoned.
Application 17/514,131 is a continuation of application No. 17/350,093, filed on Jun. 17, 2021, abandoned.
Application 17/350,093 is a continuation of application No. 16/338,975, granted, now 11,058,704, issued on Jul. 13, 2021, previously published as PCT/US2017/054694, filed on Oct. 2, 2017.
Claims priority of provisional application 62/403,598, filed on Oct. 3, 2016.
Prior Publication US 2024/0285665 A1, Aug. 29, 2024
Int. Cl. A61K 31/7076 (2006.01); A61K 31/706 (2006.01); A61K 31/7064 (2006.01); A61K 39/395 (2006.01); C07H 19/20 (2006.01); C07H 19/207 (2006.01); C07H 19/23 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61K 39/3955 (2013.01); C07H 19/20 (2013.01); C07H 19/207 (2013.01); C07H 19/23 (2013.01)] 24 Claims
 
1. A process for preparing a CD73 inhibitor, said process comprising:
a) contacting a compound of formula (i):

OG Complex Work Unit Chemistry
with a protected analog of ribofuranose to form a protected analog of compound of formula (iii):

OG Complex Work Unit Chemistry
 and
b) contacting the protected analog of compound of formula (iii) with cyclopentyl amine to form a protected analog of compound of formula (iv):

OG Complex Work Unit Chemistry